STAR-LIFE: a Post-market Registry on MINIject

Launched by ISTAR MEDICAL · Feb 25, 2022

Keywords

ClinConnect Summary

The STAR-LIFE trial is a study designed to gather real-world information about a device called MINIject, which is used to treat open-angle glaucoma, a common eye condition that can lead to vision loss. This registry is important because it helps researchers understand how well the MINIject works in everyday situations after it has been approved for use. The trial is currently looking for participants aged 18 and older who have been diagnosed with open-angle glaucoma and are set to receive the MINIject device.

To take part in the trial, individuals must be able to give their consent and should not have other types of glaucoma or certain eye conditions. Those who join the study will be monitored to see how the MINIject affects their eye health over time. This trial is open to everyone, regardless of gender, and aims to ensure that the MINIject is safe and effective for a diverse group of patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 18+ years
• • diagnosed with open angle glaucoma, who has been or will be implanted with CE-marked MINIject
• • able to give consent
• Exclusion Criteria:
• • eyes with angle closure glaucoma
• • eyes with traumatic, malignant, uveitic or neovascular glaucoma or discernible congenital anomalies of the anterior chamber angle
• • patients with known intolerance or hypersensitivity to silicone
• • patients unable to give consent